AstraZeneca plc (LON:AZN) Receives “Neutral” Rating from BNP Paribas
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating restated by equities researchers at BNP Paribas in a research note issued to investors on Friday.
Several other research firms have also recently weighed in on AZN. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Liberum Capital reiterated a “buy” rating and issued a GBX 5,500 ($71.82) price objective on shares of AstraZeneca plc in a report on Monday, June 5th. Deutsche Bank AG dropped their price objective on AstraZeneca plc from GBX 5,500 ($71.82) to GBX 5,350 ($69.86) and set a “buy” rating for the company in a report on Friday, April 28th. Credit Suisse Group reiterated a “neutral” rating and issued a GBX 5,000 ($65.29) price objective on shares of AstraZeneca plc in a report on Monday, June 19th. Finally, HSBC Holdings plc restated a “reduce” rating and issued a GBX 4,200 ($54.84) target price on shares of AstraZeneca plc in a research note on Friday, May 5th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of GBX 5,251.80 ($68.58).
Shares of AstraZeneca plc (AZN) opened at 5151.00 on Friday. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock’s 50 day moving average price is GBX 5,238.22 and its 200 day moving average price is GBX 4,845.66. The company’s market cap is GBX 65.21 billion.
COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (LON:AZN) Receives “Neutral” Rating from BNP Paribas” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/21/astrazeneca-plc-lonazn-receives-neutral-rating-from-bnp-paribas.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.